Search clinical trials for: Rosiglitazone XR

Total 746 results

GlaxoSmithKline

Terminated

Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers

Alzheimer's Disease

Australia, Spain, United States, Bulgaria, Germany, Belgium, Canada, Hong Kong, Korea, Republic of, Portugal, Argentina, Chile, Greece, Slovenia, Czechia, France, Hungary, Italy, South Africa, India, Sweden, Netherlands, Philippines, ... and more
GlaxoSmithKline

Terminated

Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers

Alzheimer's Disease

United States, Bulgaria, Germany, Estonia, Korea, Republic of, China, Greece, Hungary, Russian Federation, Philippines, Austria, Chile, Mexico, Croatia, New Zealand, Peru, Puerto Rico, United Kingdom
GlaxoSmithKline

Completed

PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers (Rosi XR)

Alzheimer's Disease

Germany
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes

Congestive Heart Failure

United States
GlaxoSmithKline

Completed

The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis

Arthritis, Rheumatoid

Lithuania, United Kingdom
GlaxoSmithKline

Terminated

Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease

Alzheimer's Disease

United Kingdom
J JESUS VENEGAS, MD
Instituto Mexicano del Seguro Social; National Council of Science and Technology...

Completed

Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients.

Insulin Resistance
Solvay Pharmaceuticals

Completed

A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers

Type 2 Diabetes Mellitus

United Kingdom
Centre Hospitalier Universitaire Dijon

Completed

Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins

Type 2 Diabetes

France
GlaxoSmithKline

Completed

Efficacy and Safety In Poorly Controlled Type 2 Diabetics

Diabetes Mellitus, Type 2
GlaxoSmithKline

Completed

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes

Diabetes Mellitus, Type 2
GlaxoSmithKline

Completed

Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.

Neuropathy, Diabetic

Netherlands
Medstar Health Research Institute
GlaxoSmithKline

Terminated

Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS

Metabolic Syndrome

United States
Baskent University

Completed

Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

Obesity | Type 2 Diabetes Mellitus

Turkey
Hospital Authority, Hong Kong

Unknown

Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?

Cardiovascular Diseases | Kidney Diseases | Chronic Disease

China
GlaxoSmithKline

Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)

Alzheimer's Disease

United States, Australia, Spain, Bulgaria, Poland, Germany, Philippines, Singapore, Belgium, Canada, Hong Kong, Korea, Republic of, Finland, Slovenia, Czechia, France, South Africa, Sweden, Netherlands, Malaysia, United Kingdom, S...
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Rosiglitazone in Treating Patients With Liposarcoma

Sarcoma

United States
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH)

Terminated

Rosiglitazone in Treating Patients With Pituitary Tumors

Brain and Central Nervous System Tumors

United States
Stanford University

Terminated

Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy

Dilated Cardiomyopathy

United States
University of California, San Francisco
National Cancer Institute (NCI)

Unknown

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

Head and Neck Cancer

United States
Charite University, Berlin, Germany

Completed

11ß-HSD1 and Metabolic Syndrome

Metabolic Syndrome | Impaired Glucose Tolerance

Germany
University of Calgary
GlaxoSmithKline

Terminated

Glitazones and Endothelial Function (GATE)

Diabetes Mellitus

Canada
Leiden University Medical Center

Terminated

Rosiglitazone and Insulin Resistance in Renally Impaired Patients

Insulin Resistance | Chronic Kidney Disease

Netherlands
Technische Universität Dresden

Completed

Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone.

Healthy Subjects

Germany
GlaxoSmithKline

Completed

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Canada
GlaxoSmithKline

Completed

Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

Diabetes Mellitus, Type 2

United States
Creighton University

Completed

The Use of Rosiglitazone to Treat Asthma

Asthma

United States
Radboud University Medical Center
GlaxoSmithKline

Completed

The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.

Ischemia-Reperfusion Injury | The Metabolic Syndrome

Netherlands
US Department of Veterans Affairs

Completed

Insulin, Neurogenetics and Memory in Alzheimer's Disease

Alzheimer Disease

United States
Association pour la Recherche sur les Maladies...

Completed

A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis (FLIRT)

Non Alcoholic Steatohepatitis

France
Exelixis

Completed

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Renal Cell Carcinoma | Papillary Thyroid Cancer | Follicular Thyroid Cancer | Huerthle Cell Thyroid Cancer

United States
University of Texas Southwestern Medical Center
GlaxoSmithKline; Biosite

Completed

Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride

Diabetes Mellitus, Type 2

United States
Eisai Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

Obesity

United States
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH)

Terminated

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Cushing's Disease

United States
University Hospital, Montpellier

Completed

Effect of Rosiglitazone

Healthy

France
GlaxoSmithKline

Completed

Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus

Non-insulin-dependent Diabetes Mellitus

United Kingdom
Central South University

Completed

Effect of Adiponectin Genetic Polymorphism on Rosiglitazone Response

Diabetes Mellitus

China
GlaxoSmithKline

Completed

Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies.

Diabetes Mellitus, Type 2

Spain, Germany, France, Austria, Italy
Stanford University

Completed

Insulin Resistance in Patients With Mood Disorder

Depression | Insulin Resistance | Bipolar Disorder

United States
Korea University Anam Hospital

Completed

The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome

Metabolic Syndrome

Korea, Republic of
University of British Columbia

Completed

Rosiglitazone (Avandia®) Treatment in HIV: Its Effect on Blood Vessels

HIV Infections | Atherosclerosis

Canada
Leiden University Medical Center

Withdrawn

Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease (Hercules)

Inflammation | Chronic Kidney Disease

Netherlands
GlaxoSmithKline

Completed

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study

Diabetes Mellitus, Type 2

Japan
University of Washington
GlaxoSmithKline; Seattle Institute for Biomedical and Clinical Research

Completed

Preferred Treatment of Type 1.5 Diabetes

Type 2 Diabetes Mellitus

United States
St. Paul Heart Clinic
GlaxoSmithKline

Completed

Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

United States
Wellstat Therapeutics

Completed

Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Canada
GlaxoSmithKline

Completed

Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)

Alzheimer's Disease

Germany
GlaxoSmithKline

Completed

A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

China
Laval University
GlaxoSmithKline

Completed

Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY Trial (VICTORY)

Diabetes | Coronary Artery Bypass Grafting

Spain, Canada

Search clinical trials for: Rosiglitazone XR

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations